The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
- Stem Cell Therapy for Inflammatory Bowel Disease
- How about the safety and efficacy of novel CAR-T therapies?
- Even mild infection with COVID-19 can trigger long-lasting neuroinflammation
- Amyotrophic Lateral Sclerosis (ALS): Two new drugs failed in clinical trials!
- The “magic drug” metformin may make people live to 120 years old!
- Why do most smokers not get lung cancer?
The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
- COVID “Arcturus” XBB.1.16: The first death in U.S.
- Dual CRISPR therapy + long-acting antiretroviral drugs to clear HIV from the body
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
According to data released by the World Health Organization, there are as many as 2.26 million new cases of breast cancer worldwide in 2020, surpassing the 2.2 million cases of lung cancer. This also means that breast cancer has replaced lung cancer as the world’s largest cancer.
A few days ago, the Cleveland Clinic in the United States announced that it will launch a human clinical trial designed to test a vaccine that can prevent triple-negative breast cancer.
Negative breast cancer is a very aggressive and deadly breast cancer. At present, some conventional drugs are not effective for triple-negative breast cancer, and they can only be prevented and treated by mastectomy.
The triple-negative breast cancer vaccine developed by the Cleveland Clinic has achieved good results in laboratory and animal tests. With the US Food and Drug Administration (FDA) approved the vaccine’s research new drug application, it means that human trials are about to start.
The trial will include 18 to 24 patients who have been treated for early triple-negative breast cancer within the past three years without tumors. They will receive three injections, two weeks apart each time.
Researchers say that triple-negative breast cancer accounts for approximately 12% to 15% of all breast cancer patients, and nearly a quarter of patients die within five years after diagnosis. This is more common in African American women and women with BRCA1 mutations.
Although the trial will only include early triple-negative breast cancer survivors with a high risk of recurrence, the researchers hope that the next step will be to vaccinate healthy people with a high risk of the disease, such as those with a BRCA1 gene mutation.
In the long run, once the test results are better, the vaccine will become a preventive vaccine for healthy women to prevent them from developing triple-negative breast cancer.
It is understood that triple-negative breast cancer refers to breast cancer in which the results of the immunohistochemical examination of the cancer tissue are negative for estrogen receptor, progesterone receptor and the proto-oncogene Her-2. With special biological behavior and clinicopathological characteristics, the prognosis is worse than other types.
The clinical manifestation of triple-negative breast cancer is an aggressive course, with a higher risk of distant metastasis, a higher chance of visceral metastasis than bone metastasis, and a higher chance of brain metastasis. The risk of distant metastasis of triple-negative breast cancer reaches its peak at 3 years, and may decrease thereafter.
The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
(source:internet, reference only)
Disclaimer of medicaltrend.org
